A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor
receptor (VEGFR), and it's anti-angiogenesis effect has been viewed in preclinical tests.
Phase I study has shown that the drug's toxicity is manageable and the maximum tolerable
daily dose is 850 mg. The purpose of this study is to determine whether apatinib can improve
progression free survival compared with placebo in patients with advanced non-squamous and
non-small cell lung cancer who failed two lines of chemotherapy.